IC50: 30.9 nM; Ki: 52 nM (somatostatin receptor 1)IC50: 345 nM (somatostatin receptor 3)

CH275 (100 nM) activates neprilysin activity, wheras treatment with cyclo-SRIF can complete this activation in vitro in primary neuron-based cell culture system, a mixture of wildtype hippocampal, cortical and striatal neuron.

CH275 (osmotic pump administration; 56 μM; two weeks) decreases the?level of neprilysin/SRIF in the App knock-in mice.CH275 directly injects into the Lacunosum molecular layer (Lmol) layer of 2-month-old App ^NL-G-F mice for four months. App ^NL-G-F mice begin to exhibit Aβ plaques at two months of age, but CH275 leads to robustly increased the expression of neprilysin in hippocampus which is paralleled by a clear reduction in Aβ plaque load in the same region, and without causing any toxic side effects.